Immatics Publishes Phase 1 Presentation on IMA203CD8 Cell Therapy in Solid Tumors
Bitget2026/10/23 11:48- Immatics published an ESMO presentation reporting Phase 1 results for its investigational PRAME-directed T-cell therapy IMA203CD8 in solid tumors.
- Objective response rate reached 51% among 90 evaluable patients; confirmed objective response rate was 41%.
- Higher-dose treatment in 20 patients with gynecologic cancers yielded a 60% objective response rate; confirmed responses reached 55%.
- Responses remained ongoing beyond 2.5 years across indications.
- Dose-limiting toxicities occurred in four of 98 patients; the maximum tolerated dose was not reached at 12.5 billion cells.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MinebeaMitsumi Shareholders to Sell 18,092,100 Shares in Secondary Offering
The U.S. Senate passes a landmark permitting reform bill to expedite grid and AI data center approvals
The U.S. Senate has passed a landmark bill that could comprehensively reform the country's energy permitting system.
Cracks in "AI trading" continue to appear, triggering a global stock sell-off, while US Treasuries are set for their longest rally in five months.
As concerns over artificial intelligence (AI) trading trends continue to deepen, the global stock market sell-off has intensified, leading investors to flock to safe-haven assets. As a result, US Treasuries are poised to experience their longest rally in nearly five months.